Andhra Petrochemicals FY26: A ₹365 Cr Cash Pile Watches Its Own Plant Go Dark

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Andhra Petrochemicals closed FY26 with revenue of ₹455.8 crore, down from ₹501.89 crore a year earlier, and a net loss of ₹15.67 crore — the second straight annual loss after ₹18.13 crore in FY25. Operating margin sat at -4%, the kind of number that needs a minus sign to be honest.

Two facts pull against each other on this data sheet. First, the company carries cash and investments of roughly ₹365 crore against a market capitalisation of ₹381 crore — a balance sheet heavier on idle money than on operating muscle. Second, the plant that is supposed to generate operating profit was shut from 17 March 2026 after HPCL stopped supplying propylene, its single raw material, amid the West Asia conflict — per the company’s own filing to the exchange.

A petrochemical maker with a strong treasury and a silent reactor is an unusual specimen: the books look solvent while the factory looks switched off. The full-year loss is attributed by management to lower product realisations and higher raw-material prices, alongside the shutdown.

The record for FY26, then, is of a company financially padded and operationally stalled. How those two states resolve is the question the year leaves open.

2 — Introduction

Incorporated in 1984 and promoted by The Andhra Sugars Ltd and the Andhra Pradesh Industrial Development Corporation, Andhra Petrochemicals manufactures oxo-alcohols at a single plant in Visakhapatnam. Its factory sits adjacent to HPCL’s refinery, from which it draws propylene under a long-term contract — a neat arrangement until the supplier stops supplying.

That is precisely what FY26 delivered. The plant was first shut from 29 October 2025 for maintenance, then kept shut on weak realisations, restarted at some point, and then suspended again from 17 March 2026 when HPCL halted propylene. The board approved the audited FY26 results on 27 May 2026 with an unmodified audit opinion, and set the 42nd AGM for 23 September 2026.

Layered on top: ICRA downgraded the company’s long-term limits to BBB+ (Negative) in February 2026, and a Fuel & Power Purchase Cost Adjustment matter produced an exceptional provision of ₹3.08 crore in FY26.

3 — Business Model: WTF Do They Even Do?

They make oxo-alcohols. Specifically 2-Ethyl Hexanol, Normal Butanol, IsoButanol and Normal Butyraldehyde — chemical intermediates whose headline use is feeding the production of DOP, a plasticiser that softens PVC. So the entire enterprise exists, at one remove, to help make plastic less brittle. Noble work, narrow lane.

The narrowness is the model’s whole personality. One product line — segmental reporting under Ind AS-108 is literally “not applicable” because there is only one segment. One key raw material, propylene. One supplier of it, HPCL, next door. A single plant. FY23 disclosures showed a top customer at 23% and the top four at 54% of sales, with roughly 97% of revenue from fixed-price manufacturing contracts.

The company does enjoy structural shelter: anti-dumping duties on imported oxo-alcohols, and a near-duopoly in domestic supply. The trouble with a fortress built on one gate is that whoever controls the gate controls you — and FY26 demonstrated the point when the gate closed and the plant simply stopped.

Does a protected market mean much when the single input pipe can be turned off by a war two continents away?

4 — Financials Overview

Figures are consolidated, in ₹ crore.

The March quarter posted a slim ₹1.38 crore profit — but the path there is instructive. Profit before exceptional items was ₹1.32 crore; an FPPCA exceptional charge dragged pre-tax to a ₹1.76 crore loss; then a tax credit of ₹3.14 crore lifted the bottom line back into the black. The arithmetic shows a profit manufactured below the operating line, not above it.

Quarterly revenue of ₹79.32 crore is down 44.7% YoY, consistent with a plant that spent much of the period idle.

5 — Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

With FY26 earnings negative, there is no positive figure for the market to apply an earnings multiple to — the P/E is simply absent. The market is instead pricing the company at 0.75 times book value, below 1.

What the market appears to be pricing here is not the income statement but the balance sheet: cash and investments of roughly ₹365 crore sit behind a ₹381 crore market cap, so the operating business is being valued at close to nothing above its treasury. ROE of -2.45% against a five-year average of 11.4%, and ROCE of -1.62% against a peer median of 9.47%, frame the gap between what this asset base has earned historically and what it earned this year.

The one factual observation: at sub-book pricing with negative returns, the market is valuing the cash, not the chemistry.

6 — What’s Cooking

• Plant suspended, 17 March 2026. HPCL stopped propylene supply citing the Iran–USA/Israel war; operations to resume on restoration, per the filing.
• ICRA downgrade, February 2026. Long-term limits (₹35 crore and ₹57.18 crore) cut to BBB+ (Negative); short-term ₹2 crore A2+ reaffirmed.
• FPPCA exceptional item, ₹3.08 crore. Provision made in FY26 for AP electricity regulator charges relating to FY23 and FY24; the company has challenged the orders before APTEL.
• No dividend for FY26, after payouts in prior years.
• VPA land-lease dispute over the plot the plant stands on continued through the courts, with a division-bench judgement on 3 November 2025.

Five real events, none of them the kind a company writes home about.

7 — Balance Sheet

Assets equal liabilities in every column. Three observations on the numbers:

• Net worth has eroded for two straight years, from ₹555.69 crore to ₹505.35 crore — equity quietly being spent on losses rather than built.
• The ₹82.22 crore “borrowings” line is largely lease liability under Ind AS 116; ICRA notes long-term debt is nil, so the genuine leverage is closer to a rounding error than a risk.
• Total assets shrank ₹73 crore over two years even as the cash hoard stayed largely intact — the contraction is in the working parts, not the war chest.

A balance sheet this liquid losing money is a rare sight: the safety net is intact while the trapeze artist has gone home.

8 — Cash Flow: Sab Number Game Hai

The three years tell three different stories. FY24 generated real operating cash; FY25 burned ₹56.73 crore from operations and plugged the hole by selling financial assets; FY26 limped back to ₹13.05 crore positive operating flow. Financing was a steady outflow throughout — interest, leases and the FY25 dividend leaving the building. Operating cash that swings from +103 to -57 to +13 in three years isn’t a trend; it’s a pulse.

9 — Ratios: Sexy or Stressy?

• ROE -2.45% — the equity isn’t working part-time, it’s working against itself this year.
• ROCE -1.62% — capital deployed earned less than zero; the assets sat in the building doing impressions of productivity.
• PAT Margin -3.44% — every ₹100 of sales left ₹3.44 behind on the way out.
• D/E 0.16 — almost entirely lease, the one ratio on this sheet with nothing to apologise for.

10 — P&L Breakdown: Show Me the Money

(EBITDA = PBT + Interest + Depreciation.)

The trajectory is a cliff. Revenue fell 42% across two years, but EBITDA’s collapse is the real story: ₹109.57 crore in FY24 to barely ₹2 crore since. With operating profit near zero, the only thing keeping PAT from being far worse is other income of ₹22.25 crore — the treasury’s interest doing the heavy lifting the plant could not. A manufacturer whose financial earnings outweigh its manufacturing earnings has, for the moment, become a chemical company in name and an investment vehicle in practice.

11 — Peer Comparison

Andhra is the smallest house on the street by an order of magnitude — quarterly revenue of ₹79.32 crore against peers running into thousands of crore. Where peers carry positive double-digit P/Es, Andhra has no earnings to multiply at all this year. Tata Chemicals’ ₹2,116 crore quarterly loss shows the commodity-chemical cycle isn’t sparing the giants either; Andhra is simply experiencing the same weather in a much smaller boat.

12 — Miscellaneous: Shareholding & Promoters

Promoter holding has been frozen at 45.04% across every quarter on record, split between The Andhra Sugars Ltd (33.05%), APIDC (10.80%) and Jocil (1.19%). The promoter is itself a listed chemical group, so this is a corporate parent rather than an individual — which keeps the conduct boring in the good way. Institutional interest is effectively nil at under 1%, leaving the public to hold the majority of a sub-₹400 crore company through a two-year loss streak.

13 — Corporate Governance: Angels or Devils?

The record reads clean. Auditors C V Ramana Rao & Co. issued an unmodified opinion on the FY26 results. Pledged promoter shares stand at 0%. There is no resignation, fraud flag, or related-party alarm in the dump.

What does appear are two disclosed legal/regulatory matters, stated as facts: the FPPCA charges of ₹3.08 crore and ₹3.32 crore challenged before APTEL, and the long-running dispute with Visakhapatnam Port Authority over the plant’s land lease, now resolved at the division-bench stage and pending lease execution. Both are disclosed in the filing and provided for or accounted under Ind AS 116. Governance here is unremarkable — which, in this section, is a compliment.

14 — Industry Roast & Macro Context

The oxo-alcohol business is a study in dependency. Domestic producers shelter behind anti-dumping duties and a near-duopoly, which sounds cosy until you remember the entire sector runs on propylene drawn from refineries it does not own. The protection keeps importers out; it does nothing when the input itself stops flowing — as a geopolitical conflict thousands of kilometres away just proved by idling a plant in Visakhapatnam.

Downstream, demand rides on PVC plasticisers, tying the sector’s fortunes to construction and consumer plastics cycles it cannot influence. Squeezed between a single upstream pipe and a price-taking downstream market, the oxo-alcohol maker’s margin is a sandwich filling — whatever the two slices leave behind. FY26’s negative operating margin is what happens when both slices press at once.

15 — EduInvesting Verdict

The central tension of FY26 is plain: a company with the treasury of a survivor and the income statement of a casualty. The cash explains why the market pays 0.75 times book; the idle plant explains why it pays no more.

A balance sheet with nothing to fear, and a reactor with everything to restart.